Lexicon Pharmaceuticals, Inc. · NASDAQ:LXRX
Lexicon Pharmaceuticals — 42nd Annual JPMorgan Healthcare Conference 2024
35 slides from Lexicon Pharmaceuticals's conference presentation, January 2024
Slide 1: 42nd Annual JPMorgan Healthcare Conference
42 Annual JPMorgan nd Healthcare Conference January 2024 Lonnel Coats Chief Executive Officer and Director
Slide 2: Forward-Looking Statements
Forward-Looking Statements • This presentation, including any oral presentation accompanying it, contains “forward-looking statements,” including statements about Lexicon’s strategy and operating performance and events or developments that we expect or anticipate will occur in the future, such as pr
Slide 3: Lexicon Evolution and 2023 Accomplishments
Lexicon Evolution and As Lexicon continues to evolve, we remain steadfast in our mission to bring new therapeutic solutions to patients in need. 2023 Accomplishments The resulting resource provides us with unique Advancing from perspective and In 2023 we took the next the foundational understanding
Slide 4: 2023 - A Transformative Year for Lexicon
2023 - A Transformative Year for Lexicon Approval of INPEFA for Heart Failure and Advancement of LX9211 into Late-Stage Development Commercial Launch of INPEFA Underway in Late-Stage Development of LX9211 Initiated in Heart Failure Diabetic Peripheral Neuropathic Pain (DPNP) • Achieved FDA approval
Slide 5: LX9211 for Neuropathic Pain
LX9211 for Neuropathic Pain 5
Slide 6: LX9211 Potential to Redefine Standard of Care for DPNP
LX9211 has the Potential to Redefine the Standard of Care for Patients Suffering with DPNP – Fast Track Designation by FDA HIGH UNMET MEDICAL PROOF OF CONCEPT NEED ACHIEVED ADVANCEMENT OF SIGNIFICANT CLINICAL PROGRAM COMMERCIAL UNDERWAY OPPORTUNITY Patient Data: Decision Resources Group, Landscape &
Slide 7: Significant Commercial Opportunity and High Unmet Need
Significant Commercial Opportunity and High Unmet Need Neuropathic Pain • 20 million+ Americans experience neuropathic pain Number of Patients in the U.S. • Approximately 5 million DPNP patients in the U.S. • Current standard of care does not eliminate neuropathic pain for most patients, and many ex
Slide 8: AAK1 as Most Compelling Target for Neuropathic Pain
Lexicon Identified AAK1 as the Most Compelling Target for Neuropathic Pain among the Nearly 5,000 Targets Evaluated in the Genome5000 Program Genome5000 Supported Selection of AAK1 over Other Putative Genetic Knockouts of AAK1 Demonstrated Targets with Less Compelling Profiles for Neuropathic Pain R
Slide 9: Phase 2 Study of LX9211 in DPNP Design
Phase 2 Study of LX9211 in Diabetic Peripheral Neuropathic Pain was Designed to Demonstrate Effect Versus Placebo RELIEF-DPN-1: Efficacy, Safety, and PK of LX9211 in Patients with Diabetic Peripheral Neuropathic Pain (DPNP) Single-blind Screening Period Placebo Double-blind Treatment Single-blind Sa
Slide 10: LX9211 Achieved the Primary Endpoint in RELIEF-DPN-1
LX9211 Achieved the Primary Endpoint in RELIEF-DPN-1 Clinically and statistically significant reduction in average daily pain score (ADPS) at Week 6 compared to placebo* in the low dose arm with results that plateaued in the high dose arm Effect on ADPS consistent across age, sex, use of baseline DP
Slide 11: Benefits in Burning Pain and Pain Interference with Sleep
Significant and Clinically Meaningful Benefits Demonstrated in Both Burning Pain and Pain Interference with Sleep Both are commonly reported challenges experienced by DPNP patients LS MEAN CHANGE FROM BASELINE LS MEAN CHANGE FROM BASELINE IN BURNING PAIN IN INTERFERENCE IN SLEEP 11
Slide 12: The PROGRESS Phase 2b Study
The PROGRESS Phase 2b Study – Patient Enrollment Underway, First Data Read-out Expected in Q2 ‘25 Patient Safety Follow-up Treatment Period Population LX9211 10 mg • Adult patients with a LX9211 20 mg diagnosis of T1DM or T2DM with moderate R LX9211 20 mg for 7 days/10 mg thereafter to severe diabet
Slide 13: LX9211 Has Entered Late-stage Development for DPNP
LX9211 Has Entered Late-stage Development for DPNP • Potential first-to-market opportunity with very few novel treatments in development for DPNP or neuropathic pain generally • DPNP represents the largest and fastest growing neuropathic pain market opportunity • FDA feedback obtained in Q2 2023 and
Slide 14: INPEFA (sotagliflozin) for Heart Failure
02 INPEFA® (sotagliflozin) for Heart Failure 14
Slide 15: INPEFA Approved and Commercially Launched for Heart Failure
INPEFA (sotagliflozin) Approved and Commercially Launched for Treatment of Heart Failure INPEFA granted broad INPEFA reduced the risk of total Recently adopted guidelines label in heart failure (HF), occurrence of cardiovascular death, support use of SGLT inhibitors across full range of left hospita
Slide 16: Heart Failure is a Large and Growing Problem
Heart Failure is a Large and Growing Problem, with High Patient Burden and Costs Driven by Repeated Hospitalizations ~6.7 #1 1.3 million hospitalizations million heart failure cause of admissions to for heart failure annually prevalence in the U.S. hospital for Americans 65+ in the US (in 2019) ~8.5
Slide 17: Heart Failure is a Large and Fast-Growing Market
Heart Failure is a Large and Fast-Growing Market with the SGLT Class – including INPEFA – Poised for Significant Growth Strong Growth of SGLT Under-penetrated Market 1 of 3 SGLT inhibitors use in heart failure1 with 1 in 10 HF prescriptions indicated for heart failure for an SGLT inhibitor2 Anticipa
Slide 18: INPEFA Inhibits Two Targets With Cardiometabolic Profiles
INPEFA Inhibits Two Targets With Important Cardiometabolic Profiles Sotagliflozin is an oral inhibitor of sodium-glucose cotransporters -1 (SGLT1) and -2 (SGLT2), responsible for absorption (or reabsorption) of sodium and glucose Proximal convoluted tubule (S1) SGLT2 SGLT2 is expressed in the kidney
Slide 19: Elevations of SGLT1 and SGLT2 Associated with Heart Failure
Elevations of SGLT1 and SGLT2 are Separately Associated with Heart Failure and Other Cardiometabolic Diseases Left ventricle: Kidney: SGLT1 elevated in SGLT2 elevated in • Heart failure1-4 • Diabetic nephropathy6 • Dilated cardiomyopathy1 • Heart failure7,a • Ischemic heart disease with/without type
Slide 20: Human Genetics Supports SGLT1 as a Target
Human Genetics Provides Further Support SGLT1 as a Target for Heart Failure and Cardiometabolic Disease Naturally-Occurring SGLT1 Reduced Function Variant8 Adjusted HR (95% CI) P Value 0.81 (0.69– Incident diabetes 0.006 0.94) 0.74 Heart failure 0.0046 (0.60‒0.91) 0.80 (0.71– Risk of HF or death 0.0
Slide 21: INPEFA First SGLT Inhibitor Labeled with Reduction of CV Death and HF Events
INPEFA is the First and Only SGLT Inhibitor Labeled with a Reduction of CV Death and HF Events in Patients Initiated on Therapy in the Hospital or Promptly Following Discharge 98 100 SOLOIST-WHF Primary Endpoint Data: Placebo INPEFA reduced the risk of total occurrence of CV death, hospitalization f
Slide 22: INPEFA Reduced CV Death and HF Events Over 30 and 90 Days
INFEFA Reduced CV Death and HF Events by 50% Over the First 30 and 90 Days Post Discharge 20 Placebo Cardiovascular Death or HF-Related Event (%) 15 10 INPEFA is the Only SGLT Sotagliflozin Inhibitor to Demonstrate a Significant Reduction in 30-day Hospital 5 Readmissions 0 0 15 30 45 60 75 90 Days
Slide 23: INPEFA Targeting: ~150 Cardiovascular Specialists
INPEFA Targeting: ~150 Cardiovascular Specialists Focused on Highest Volume HF Prescribers Focused Targeting ~9,200 total HCP targets at launch Segment A: Prioritized executional focus: ~2200 HCPs • Segments A&B ~60% of HF TRx volume Segment B ~2700 HCPs Primary focus is Cardiologists specializing i
Slide 24: INPEFA Coverage Grew in Q4 2023
INPEFA Coverage Grew in Q4 2023 With Broadening Access Coverage Expected Throughout 2024 Selected Accounts Current Market Access Status Plan Name/Formulary Channel Effective Date % OF TOTAL LIVES CVS/Aetna EQWP Medicare 12/1/2023 COVERED AS OF Express Scripts – Premier Access Medicare 11/1/2023 DECE
Slide 25: New Writers and Submitted Claims Continued to Grow
New Writers & Submitted Claims Have Continued to Grow throughout Q4* 2023 demonstrating broadening adoption of INPEFA SUBMITTED CLAIMS Q2, Q3 AND PARTIAL Q4 ~1200 HCP’s submitted claims through Q4 Total claims (+260% vs. Q3) 10,093 4,611 10 Q2 Q3 Q4 25 *Submitted claims through week of Dec 1 (pendin
Slide 26: INPEFA Opportunity for Life-Cycle Management
03 INPEFA (sotagliflozin) Opportunity for Life-Cycle Management 26
Slide 27: Life-Cycle Management Opportunity for INPEFA in HCM
Life-Cycle Management Opportunity for INPEFA (sotagliflozin) in HCM Hypertrophic Cardiomyopathy (HCM) ▪ Indication with strong scientific rationale and that would be unique to sotagliflozin among SGLT inhibitors ▪ Significant market opportunity with minimal existing treatments – Estimated ~1 million
Slide 28: INPEFA Efficacy Across LVEF Points to HCM Opportunity
To TOP INPEFA’s Efficacy Data Across LVEF is Compelling for Heart Failure... And Points to Potential Life-Cycle Management Opportunity in HCM Treatment effect of sotagliflozin was observed in SOLOIST and SCORED patients, regardless of LVEF • All patients from SOLOIST HR Treatment Effect vs LVEF for
Slide 29: SCORED Data in Left Ventricular Hypertrophy Without Hypertension
SCORED Data in Patients with Left Ventricular Hypertrophy without Hypertension Offer Perspective on Potential Application in Patients with HCM Sotagliflozin Reduces the Risk of Cardiovascular Events in Patients With Left Ventricular Hypertrophy Without Hypertension: A Post Hoc Analysis From SCORED •
Slide 30: FDA Feedback Supports Potential for INPEFA sNDA for HCM
FDA Feedback Supports Potential for INPEFA sNDA for HCM Based on Single Successful Phase 3 Study with KCCQ Primary Endpoint Primary endpoint: Change from baseline in KCCQ Clinical Summary Scale (CSS) score Proposed indication: INPEFA is indicated to improve symptoms and physical limitations in adult
Slide 31: Summary and 2024 Areas of Focus
04 Summary and 2024 Areas of Focus 31
Slide 32: Lexicon in 2024 – Key Business Objectives
Lexicon in 2024 – Key Business Objectives Progress Advance LX9211 Opportunities for Further Accelerate for Diabetic Partnership, Launch of INPEFA Peripheral Growth and for Heart Failure Neuropathic Pain Expansion 32
Slide 33: Leveraging Scientific Platform to Build Strong Pipeline
Lexicon – Leveraging Scientific Platform and Expertise to Build Strong Pipeline Opportunities for Growth and Partnership Preclinical Phase 1 Phase 2 Phase 3 Registration Approved INPEFA® (sotagliflozin) Approved for Heart Failure LX9211 Novel Non-Opioid Diabetic Peripheral Neuropathic Pain (DPNP) so
Slide 34: Thank You
u Lexicon pharmaceuticals Thank You PRECISION SCIENCE. PIONEERING MEDICINE. PATIENT DRIVEN. COMMON
Slide 35: Q&A
u Lexicon pharmaceuticals Q&A PRECISION SCIENCE. PIONEERING MEDICINE. PATIENT DRIVEN. COMMON
Lexicon Pharmaceuticals — 42nd Annual JPMorgan Healthcare Conference 2024 on 6ix